CBG-006 / Carbiogene Therap 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CBG-006 / Carbiogene Therap
ChiCTR2100044169: Clinical study of autologous T cells modified with ILT3 chimeric antigen receptor for relapsed/refractory acute myeloid leukemia (M4/M5)

Recruiting
N/A
25
 
Anti-ILT3 CAR-T cells
Zhejiang Provincal People's Hospital; Zhejiang Provincal People's Hospital, Key R&D Program of Zhejiang Province (No. 2019C03036)/Carbiogene Therapeutics Co. Ltd.
Acute myeloid leukemia (M4/M5)
 
 
ChiCTR2100044163: Clinical study of autologous T cells modified with ILT3 chimeric antigen receptor for relapsed/refractory acute myeloid leukemia (M4/M5)

Recruiting
N/A
25
 
Anti-ILT3 CAR-T cells
Zhejiang Provincal People's Hospital; Zhejiang Provincal People's Hospital, Key R&D Program of Zhejiang Province (No. 2019C03036)/Carbiogene Therapeutics Co. Ltd.
Acute myeloid leukemia (M4/M5)
 
 

Download Options